Ann: Capital Raising Presentation, page-150

I feel for the long term holders, seeing such an erosion of your investment is tough. It's happened to be more and it does hurt.
However on the flip side, for new shareholders this is looking very attractive.

With $20M in the bank and several catalysts due that could move the needle on positive results, the risk of dilution in the near future is eliminated and the only remaining risk is on the clinical results. Withstanding that, we are looking at a pretty well established patent that carries intrinsic value in of itself, which I would consider is worth several million.

With tax loss season coming up, its no surprise many will write this off so the downward trajectory is likely to continue for a couple of months.
Wether you get in at 13c or now, the risk reward here is very attractive for new investors like myself.

I am deeply empathic to exisiting investors that have lost money on this, such is always the possibility when investing in start-ups and serves as a reminder why you should never invest more than you are willing to loose.

My fingers are crossed for an easy 1x bounce if the team can finally deliver some catalysts.